Closed
The Marked Chart Wire · Health
Eikon Therapeutics
Eikon Therapeutics stated that EIK1001, used with standard treatments, showed lasting results in advanced non-small cell lung cancer. The company said the side effect profile allows for outpatient care.
New to this? Read: Reading a stock chart
Lung Cancer
Hutchmed announced that its Safron Phase III study showed a 45 percent reduction in disease progression or death risk for patients with specific lung cancer mutations when using Orpathys with Tagrisso instead of chemotherapy.
BeOne Medicines
BeOne Medicines presented ESMO data for its experimental bispecific antibody. The drug showed a 36 percent confirmed response rate in advanced liver cancer cases with a good safety profile at the Phase 3 dose.
Agenus
Agenus disclosed Sunday that 72 percent of patients with locally advanced dMMR colon cancer showed no residual disease at surgery after six weeks of treatment. The trial also met its primary endpoint, with 83 percent achieving a major pathologic response.
Lung Cancer
Updated findings from a study on first-line non-small cell lung cancer showed lasting benefits when pairing Merck's KEYTRUDA with Eli Lilly's olomorasib.
Pumitamig
BioNTech and Bristol Myers Squibb released Phase 2 data showing a 36.7 percent objective response rate for pumitamig combined with docetaxel in advanced non-small cell lung cancer.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.